All In Biotech

Drug Trial Radar · NCT06222125

A Study of HB0025 Injection in Patients With Advanced Renal Cancer

A Phase II, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of HB0025 in Patients With Advanced Renal Cancer

Last checked: Nov 19, 2026Latest source record: Jan 24, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

100

Planned (sponsor's estimate)

Start

Jan 30, 2023

Primary completion

Jan 30, 2025

Study completion Dec 30, 2025

Sponsor

Lead sponsor
Huabo Biopharm Co., Ltd.Industry
Sponsor type
Industry
First posted
Jan 24, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

It is a phase II open label, multicenter study to assess the safety, tolerability, pharmacokinetics, and efficacy of HB0025 in patients with advanced clear cell renal cell carcinoma (ccRCC).

Conditions

  • Renal Cancer

Interventions

  • HB0025Drug

    HB0025 IV every 2 weeks (q2w)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective response rate (ORR)Time frame: up to 24 mouths

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.